cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29525279.v1
title: Clinical burden of pneumococcal disease among adults in France: A retrospective cohort study

description: Pneumococcal disease (PD) is associated with high morbidity and mortality, specifically among individuals ≥65 years of age and those with underlying medical conditions (UMCs). This retrospective cohort study estimated the clinical burden of PD in adults ≥18 years of age with or without UMCs in France. Data were obtained from the French National Health Data System for four yearly cohorts (1 January 2015–31 December 2018). Characteristics of patients with UMCs, with or without PD (UMC population), and the incidence rate and lethality rate of PD leading to hospitalization (in-patient PD population), stratified by age and risk status, were described. In the UMC population (<i>n</i> = 7,947,622; mean age: 65 years), the incidence rate of in-patient PD episodes was 121.98 per 100,000 person-years and was highest among individuals ≥65 years of age (138.52) and in those considered medium-risk (102.45) or high-risk (165.77). In the in-patient PD population (<i>n</i> = 41,885), 59.6% were ≥65 years of age; 1-year all-cause mortality following the initial in-patient PD episode was 26.5%. Individuals ≥65 years of age (regardless of risk status) had a higher risk of PD leading to hospitalization than individuals 18–64 years of age. This study shows a high burden of PD in France due to in-patient PD among adults with UMCs, particularly in those ≥65 years of age, despite their eligibility for pneumococcal vaccination. This highlights the need for higher vaccination coverage, supported by the recent extension of vaccination to all people ≥65 years of age, regardless of their health risk status.
DOI: 10.6084/m9.figshare.29668590
title: Single-cell analysis unravels the role of NK cells and monocytes in the control of SARS-CoV-2 breakthrough infections in vaccinated individuals

description: Analyzing the antiviral response of natural killer (NK) cells and monocytes is essential to understanding vaccine protection in an immunized population facing SARS-CoV-2 variant breakthrough infections (BTIs). In this study, in peripheral blood mononuclear cells (PBMCs) from vaccinated individuals with SARS-CoV-2 infections, we observed an increase in adaptive CD57<sup>+</sup>NKG2C<sup>+</sup> NK cells and classical monocytes (CMs). Single-cell sequencing analysis showed that the transcriptomic profiles of IFN-induced IFIT3 and other IFN-stimulated genes exhibited marked upregulation in NK cells, defined as CD56<sup>dim</sup>CD57<sup>+</sup>NKG2C<sup>+</sup>IFIT3<sup>+</sup> NK cells. Additionally, CM in the blood showed characteristics indicative of differentiation into dendritic cells (DCs) and macrophages, which further evidenced their potential antiviral functions. Our study indicates that a vaccinated population rapidly activates an antiviral innate immune response following a BTI, thus revealing a link to the control of viral replication during SARS-CoV-2 BTIs.
DOI: 10.6084/m9.figshare.29668590.v1
title: Single-cell analysis unravels the role of NK cells and monocytes in the control of SARS-CoV-2 breakthrough infections in vaccinated individuals

description: Analyzing the antiviral response of natural killer (NK) cells and monocytes is essential to understanding vaccine protection in an immunized population facing SARS-CoV-2 variant breakthrough infections (BTIs). In this study, in peripheral blood mononuclear cells (PBMCs) from vaccinated individuals with SARS-CoV-2 infections, we observed an increase in adaptive CD57<sup>+</sup>NKG2C<sup>+</sup> NK cells and classical monocytes (CMs). Single-cell sequencing analysis showed that the transcriptomic profiles of IFN-induced IFIT3 and other IFN-stimulated genes exhibited marked upregulation in NK cells, defined as CD56<sup>dim</sup>CD57<sup>+</sup>NKG2C<sup>+</sup>IFIT3<sup>+</sup> NK cells. Additionally, CM in the blood showed characteristics indicative of differentiation into dendritic cells (DCs) and macrophages, which further evidenced their potential antiviral functions. Our study indicates that a vaccinated population rapidly activates an antiviral innate immune response following a BTI, thus revealing a link to the control of viral replication during SARS-CoV-2 BTIs.
DOI: 10.6084/m9.figshare.30264811
title: A novel anti-PcrV monoclonal antibody inhibits toxin-mediated cytotoxicity and enhances survival in mouse models of <i>Pseudomonas aeruginosa</i> infection

description: Due to toxin-mediated damages and biofilm-associated persistence, <i>Pseudomonas aeruginosa</i> (PA) infection remains a critical threat in hospital settings. Monoclonal antibody (mAb) therapy represents a promising strategy for combating PA infections due to its high specificity and significantly reduced potential for resistance development. The highly conserved structural protein PcrV, a component of the type III secretion system, is a key target for immunotherapies against PA. In this study, we developed mAb 10H6, which recognizes a novel linear epitope PcrV<sub>94–111</sub> (Leu94–Glu111) within the PcrV. This mAb inhibited ExoU secretion in a dose-dependent manner and conferred significant protection in both preventive and therapeutic models of acute PA pneumonia. Furthermore, 10H6 effectively inhibited biofilm formation <i>in vitro</i> and conferred robust protective effects in chronic PA skin wound infection models. These findings establish 10H6 as a promising therapeutic antibody for the treatment of PA infections.
DOI: 10.6084/m9.figshare.29212612
title: Systematic literature review and meta-analysis on the prevalence of rotavirus genotypes in Asia from 2015 to 2021

description: Understanding rotavirus prevalence by genotype can inform disease prevention and immunization decision-making. This systematic literature review summarized the genotype-specific prevalence of rotavirus in Asia from 2015 to 2021. We identified surveillance studies using PubMed, Embase, and Scopus databases, and used proportional meta-analysis (with the generic inverse variance method with arcsine transformation and generalized linear mixed models) to summarize genotype prevalence by region. A total of 7,601 studies were screened, and 73 studies from 16 countries were included. Data from 19,935 rotavirus samples reveal that the most common rotavirus genotypes circulating in Asia from 2015 to 2021 were G3P[8] (24%; 95% CI: 19%, 30%), G9P[8] (11%; 95% CI: 7%, 16%), G1P[8] (11%; 95% CI: 8%, 14%) and G2P[4] (8%; 95% CI: 6%, 10%). The results are comparable to estimates from the pre-vaccine licensure period. Surveillance based on sequencing data could help detect more subtle changes and further characterize the rotavirus burden in Asia. This study synthesizes data on rotavirus prevalence by genotype in Asia for the period 2015–2021. It finds G3P[8], G9P[8], G1P[8] and G2P[4] to be the most prevalent genotypes across the included countries.
DOI: 10.6084/m9.figshare.29212612.v1
title: Systematic literature review and meta-analysis on the prevalence of rotavirus genotypes in Asia from 2015 to 2021

description: Understanding rotavirus prevalence by genotype can inform disease prevention and immunization decision-making. This systematic literature review summarized the genotype-specific prevalence of rotavirus in Asia from 2015 to 2021. We identified surveillance studies using PubMed, Embase, and Scopus databases, and used proportional meta-analysis (with the generic inverse variance method with arcsine transformation and generalized linear mixed models) to summarize genotype prevalence by region. A total of 7,601 studies were screened, and 73 studies from 16 countries were included. Data from 19,935 rotavirus samples reveal that the most common rotavirus genotypes circulating in Asia from 2015 to 2021 were G3P[8] (24%; 95% CI: 19%, 30%), G9P[8] (11%; 95% CI: 7%, 16%), G1P[8] (11%; 95% CI: 8%, 14%) and G2P[4] (8%; 95% CI: 6%, 10%). The results are comparable to estimates from the pre-vaccine licensure period. Surveillance based on sequencing data could help detect more subtle changes and further characterize the rotavirus burden in Asia. This study synthesizes data on rotavirus prevalence by genotype in Asia for the period 2015–2021. It finds G3P[8], G9P[8], G1P[8] and G2P[4] to be the most prevalent genotypes across the included countries.
DOI: 10.6084/m9.figshare.30264811.v1
title: A novel anti-PcrV monoclonal antibody inhibits toxin-mediated cytotoxicity and enhances survival in mouse models of <i>Pseudomonas aeruginosa</i> infection

description: Due to toxin-mediated damages and biofilm-associated persistence, <i>Pseudomonas aeruginosa</i> (PA) infection remains a critical threat in hospital settings. Monoclonal antibody (mAb) therapy represents a promising strategy for combating PA infections due to its high specificity and significantly reduced potential for resistance development. The highly conserved structural protein PcrV, a component of the type III secretion system, is a key target for immunotherapies against PA. In this study, we developed mAb 10H6, which recognizes a novel linear epitope PcrV<sub>94–111</sub> (Leu94–Glu111) within the PcrV. This mAb inhibited ExoU secretion in a dose-dependent manner and conferred significant protection in both preventive and therapeutic models of acute PA pneumonia. Furthermore, 10H6 effectively inhibited biofilm formation <i>in vitro</i> and conferred robust protective effects in chronic PA skin wound infection models. These findings establish 10H6 as a promising therapeutic antibody for the treatment of PA infections.
DOI: 10.6084/m9.figshare.30373988
title: Recombinant <i>Mycobacterium smegmatis</i> expressing antigen 85B for immunotherapy of <i>Mycobacterium tuberculosis</i>-infected mice

description: Tuberculosis is a serious, chronic infectious disease worldwide, primarily caused by <i>Mycobacterium tuberculosis</i> (Mtb). Antigen 85B is a potential vaccine candidate for Mtb. In this study, we constructed a recombinant strain expressing Antigen 85B (rMs-Ag85B) in the <i>Mycobacterium smegmatis</i> (Ms). The immunological characteristics and the therapeutic efficacy of the vaccine were evaluated in mice. The results showed that rMs-Ag85B exhibited slow growth under static culture conditions, with a significant reduction in biofilm formation compared to the Ms strain. Immunologically, subcutaneous immunization with rMs-Ag85B induced stronger humoral and cellular immune responses. As a therapeutic vaccine, rMs-Ag85B modulated the aggregation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in spleen and lung, promoted Th1/Th2-type cytokines secretions, and increased inflammatory cytokines releases and alleviated pathological damages in the lung of Mtb infected mice. Moreover, rMs-Ag85B significantly reduced the Mtb loads in the spleen of mice. In conclusion, rMs-Ag85B vaccine provided an immunotherapeutic effect against Mtb infection and could be used as a candidate vaccine for the immunotherapy of tuberculosis.
DOI: 10.6084/m9.figshare.30373988.v1
title: Recombinant <i>Mycobacterium smegmatis</i> expressing antigen 85B for immunotherapy of <i>Mycobacterium tuberculosis</i>-infected mice

description: Tuberculosis is a serious, chronic infectious disease worldwide, primarily caused by <i>Mycobacterium tuberculosis</i> (Mtb). Antigen 85B is a potential vaccine candidate for Mtb. In this study, we constructed a recombinant strain expressing Antigen 85B (rMs-Ag85B) in the <i>Mycobacterium smegmatis</i> (Ms). The immunological characteristics and the therapeutic efficacy of the vaccine were evaluated in mice. The results showed that rMs-Ag85B exhibited slow growth under static culture conditions, with a significant reduction in biofilm formation compared to the Ms strain. Immunologically, subcutaneous immunization with rMs-Ag85B induced stronger humoral and cellular immune responses. As a therapeutic vaccine, rMs-Ag85B modulated the aggregation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in spleen and lung, promoted Th1/Th2-type cytokines secretions, and increased inflammatory cytokines releases and alleviated pathological damages in the lung of Mtb infected mice. Moreover, rMs-Ag85B significantly reduced the Mtb loads in the spleen of mice. In conclusion, rMs-Ag85B vaccine provided an immunotherapeutic effect against Mtb infection and could be used as a candidate vaccine for the immunotherapy of tuberculosis.
DOI: 10.6084/m9.figshare.30608200
title: Pharmacovigilance analysis of FcRn antagonists in the treatment of myasthenia gravis: A disproportionality analysis based on the FAERS database

description: This study aimed to evaluate the safety profiles of FcRn antagonists, efgartigimod alfa and rozanolixizumab, in the treatment of myasthenia gravis using real-world adverse event data from the FAERS database. A disproportionality analysis was conducted employing Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR) methods on reports from Q1 2022 to Q2 2025. The most frequently reported adverse events for efgartigimod alfa included falls, urinary tract infections, and symptom recurrence, with signals also detected for atrial fibrillation, peripheral neuropathy, and prostate cancer. For rozanolixizumab, common events were headache, diarrhea, and vomiting, with potential signals such as meningitis, hypersomnia, and feeding disorder. Subgroup analysis revealed gender-specific differences in adverse reactions. Most events occurred within 30 days of treatment initiation, though efgartigimod alfa showed a sustained risk beyond 180 days. The study identifies novel safety signals and highlights clinically relevant risk patterns, supporting enhanced monitoring in clinical use. It is crucial to emphasize that this disproportionality analysis is exploratory in nature and identifies potential associations, which do not establish causality and require confirmation through further dedicated studies.
DOI: 10.6084/m9.figshare.30608200.v1
title: Pharmacovigilance analysis of FcRn antagonists in the treatment of myasthenia gravis: A disproportionality analysis based on the FAERS database

description: This study aimed to evaluate the safety profiles of FcRn antagonists, efgartigimod alfa and rozanolixizumab, in the treatment of myasthenia gravis using real-world adverse event data from the FAERS database. A disproportionality analysis was conducted employing Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR) methods on reports from Q1 2022 to Q2 2025. The most frequently reported adverse events for efgartigimod alfa included falls, urinary tract infections, and symptom recurrence, with signals also detected for atrial fibrillation, peripheral neuropathy, and prostate cancer. For rozanolixizumab, common events were headache, diarrhea, and vomiting, with potential signals such as meningitis, hypersomnia, and feeding disorder. Subgroup analysis revealed gender-specific differences in adverse reactions. Most events occurred within 30 days of treatment initiation, though efgartigimod alfa showed a sustained risk beyond 180 days. The study identifies novel safety signals and highlights clinically relevant risk patterns, supporting enhanced monitoring in clinical use. It is crucial to emphasize that this disproportionality analysis is exploratory in nature and identifies potential associations, which do not establish causality and require confirmation through further dedicated studies.
DOI: 10.6084/m9.figshare.29853061
title: Using the CARD system for university-based pop-up vaccination clinics: A two-stage hybrid effectiveness-implementation study

description: Mass vaccination clinics efficiently vaccinate large numbers of people. The CARD system (Comfort, Ask, Relax, Distract) is a vaccination delivery framework that can improve the experiences of vaccine recipients and providers. This two-stage hybrid effectiveness-implementation study implemented and sustained CARD in university-based vaccination clinics involving pharmacy student vaccinators. Stage 1 was a before-and-after study conducted across four COVID-19 vaccination clinics in November-December, 2022. Stage 2 was a single cohort study whereby CARD was sustained across four COVID-19/influenza vaccination clinics in November, 2023. In both stages, vaccine recipients rated experiences relative to last vaccination (<i>primary outcome</i>) and symptoms (pain, fear, dizziness) using surveys. Pharmacy student vaccinators completed attitudes and behaviors surveys; a subsample participated in focus groups. In Stage 1, more vaccine recipients in the after period (vs. before) reported a better vaccination experience relative to their last vaccination (64.0% vs 33.6%; <i>p</i> &lt; .001; <i>n</i> = 181). Fear and pain were lower (1.1 vs. 1.7, <i>p</i> = .03; and 1.6 vs. 2.1, <i>p</i> = .02, respectively). In Stage 2, 57.4% (95% CI: 53.1%-61.6%; <i>n</i> = 542) of vaccine recipients reported a better experience. Across stages, pharmacy students had positive attitudes about acceptability, feasibility, and sustainability of CARD and reported high fidelity with CARD-recommended interventions. CARD is recommended for university-based vaccination clinics to improve vaccine recipient and provider experiences.
DOI: 10.6084/m9.figshare.29853061.v1
title: Using the CARD system for university-based pop-up vaccination clinics: A two-stage hybrid effectiveness-implementation study

description: Mass vaccination clinics efficiently vaccinate large numbers of people. The CARD system (Comfort, Ask, Relax, Distract) is a vaccination delivery framework that can improve the experiences of vaccine recipients and providers. This two-stage hybrid effectiveness-implementation study implemented and sustained CARD in university-based vaccination clinics involving pharmacy student vaccinators. Stage 1 was a before-and-after study conducted across four COVID-19 vaccination clinics in November-December, 2022. Stage 2 was a single cohort study whereby CARD was sustained across four COVID-19/influenza vaccination clinics in November, 2023. In both stages, vaccine recipients rated experiences relative to last vaccination (<i>primary outcome</i>) and symptoms (pain, fear, dizziness) using surveys. Pharmacy student vaccinators completed attitudes and behaviors surveys; a subsample participated in focus groups. In Stage 1, more vaccine recipients in the after period (vs. before) reported a better vaccination experience relative to their last vaccination (64.0% vs 33.6%; <i>p</i> &lt; .001; <i>n</i> = 181). Fear and pain were lower (1.1 vs. 1.7, <i>p</i> = .03; and 1.6 vs. 2.1, <i>p</i> = .02, respectively). In Stage 2, 57.4% (95% CI: 53.1%-61.6%; <i>n</i> = 542) of vaccine recipients reported a better experience. Across stages, pharmacy students had positive attitudes about acceptability, feasibility, and sustainability of CARD and reported high fidelity with CARD-recommended interventions. CARD is recommended for university-based vaccination clinics to improve vaccine recipient and provider experiences.
DOI: 10.6084/m9.figshare.30256455
title: Associations of altruistic factors and perceptions with intention to receive Respiratory Syncytial Virus (RSV) vaccination among older adults in China

description: Respiratory Syncytial Virus (RSV) vaccination may become available for older adults in China soon. This study was to investigate behavioral intention to receive self-financed and fully subsidized RSV vaccination among older adults in China. Associations of altruistic factors and perceptions with behavioral intention were also explored. This is a cross-sectional survey conducted in Shenzhen, China between August and October 2024. The sampling frame was Shenzhen residents aged ≥60 y with administrative health records in community health centers (0.94 million in 2021). Multistage random sampling was used. Ten community health centers were first randomly selected. Each selected community center then randomly selected 200 administrative health records of residents aged ≥60 y. A total of 1556 participants completed face-to-face interviews at community health centers. Among the participants, 15.4% and 60.1% intended to receive self-financed and fully subsidized RSV vaccination in the next year. After adjusting for significant background characteristics, general altruism was associated with higher odds of intending to receive a fully subsidized RSV vaccination, but not a self-financed vaccine. Family-oriented altruism (belief that receiving vaccination could protect family members), perceived more benefits, barriers, cue to action, and self-efficacy related to RSV vaccination were associated with higher odds of intending to receive an RSV vaccination under both cost scenarios. In addition, perceived susceptibility and severity of RSV were associated with higher intention to receive a fully subsidized RSV vaccination. The findings had implications for RSV vaccination service planning and health promotion among older adults before and after free vaccines are available in China.
DOI: 10.6084/m9.figshare.30256455.v1
title: Associations of altruistic factors and perceptions with intention to receive Respiratory Syncytial Virus (RSV) vaccination among older adults in China

description: Respiratory Syncytial Virus (RSV) vaccination may become available for older adults in China soon. This study was to investigate behavioral intention to receive self-financed and fully subsidized RSV vaccination among older adults in China. Associations of altruistic factors and perceptions with behavioral intention were also explored. This is a cross-sectional survey conducted in Shenzhen, China between August and October 2024. The sampling frame was Shenzhen residents aged ≥60 y with administrative health records in community health centers (0.94 million in 2021). Multistage random sampling was used. Ten community health centers were first randomly selected. Each selected community center then randomly selected 200 administrative health records of residents aged ≥60 y. A total of 1556 participants completed face-to-face interviews at community health centers. Among the participants, 15.4% and 60.1% intended to receive self-financed and fully subsidized RSV vaccination in the next year. After adjusting for significant background characteristics, general altruism was associated with higher odds of intending to receive a fully subsidized RSV vaccination, but not a self-financed vaccine. Family-oriented altruism (belief that receiving vaccination could protect family members), perceived more benefits, barriers, cue to action, and self-efficacy related to RSV vaccination were associated with higher odds of intending to receive an RSV vaccination under both cost scenarios. In addition, perceived susceptibility and severity of RSV were associated with higher intention to receive a fully subsidized RSV vaccination. The findings had implications for RSV vaccination service planning and health promotion among older adults before and after free vaccines are available in China.